The first-line treatment of advanced NSCLC without actionable mutations has undergone a dramatic change over the last 5 years, with the standard of care changing from chemotherapy to immune checkpoint inhibitor (ICI) monotherapy for select patients, to a variety of ICI-based combination regimens in addition to monotherapy.

This activity will provide learners with the latest developments in translational medicine for leukemia, lymphoma, and myeloma and how these developments can be incorporated into regimens to improve the outcome of patients with these diseases.